What is Omicia?
Fabric Genomics, formerly Omicia, is an AI-driven software enterprise specializing in the interpretation of complex genomic data. By providing clinically actionable insights, the company enables healthcare providers—including children's hospitals and large-scale diagnostic labs—to streamline the diagnosis of rare diseases and hereditary conditions. Their flagship enterprise platform is engineered to automate the generation of physician-ready reports, significantly reducing the time required for genomic analysis in high-stakes environments like the NICU. Through the integration of advanced machine learning algorithms, the company bridges the gap between raw sequencing data and clinical decision-making, positioning itself as a vital infrastructure provider in the modern healthcare ecosystem.
How much funding has Omicia raised?
Omicia has raised a total of $29.8M across 2 funding rounds:
Series A
$6.8M
Series B
$23M
Series A (2014): $6.8M with participation from Bay City Capital, LLC, Artis Ventures, and Casdin Capital, LLC
Series B (2016): $23M led by Ping An Ventures, ARTIS Ventures, and LDV Partners
Key Investors in Omicia
Ping An Ventures
The investment arm of Ping An Insurance Group, focusing on personal financial services, insurance, and banking sectors with a global investment mandate.
ARTIS Ventures
A venture capital firm specializing in Tech Bio and health, prioritizing data-driven life sciences companies that leverage AI to improve human health outcomes.
Casdin Capital, LLC
A specialized investment firm with deep expertise in the life sciences sector, particularly focused on diagnostics and molecular information pioneers.
What's next for Omicia?
With the backing of institutional investors, Fabric Genomics is well-positioned to expand its footprint in the clinical diagnostics market. The strategic focus moving forward likely involves deepening the integration of its AI platform within existing hospital electronic health record systems and expanding its reach into broader hereditary risk screening applications. As the demand for precision medicine continues to accelerate, the company's ability to deliver scalable, high-accuracy genomic interpretation will be a key differentiator. Future growth will likely center on enhancing the platform's diagnostic yield and expanding its commercial partnerships to solidify its role as a standard-bearer for genomic software in the clinical enterprise sector.
See full Omicia company page
